Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
Kwang Il Seo, Byung Chul Yun, Weiquan James Li, Sang Uk Lee, Byung Hoon Han, Eun Taek Park
Clin Mol Hepatol. 2017;23(1):74-79. Published online 2017 Mar 3 DOI: https://doi.org/10.3350/cmh.2016.0052
Citations to this article as recorded by 
Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation
Christina Sølund, Sofie Hallager, Martin S. Pedersen, Ulrik Fahnøe, Anja Ernst, Henrik B. Krarup, Birgit T. Røge, Peer B. Christensen, Alex L. Laursen, Jan Gerstoft, Erika Bélard, Lone G. Madsen, Kristian Schønning, Anders G. Pedersen, Jens Bukh, Nina Wei
Scandinavian Journal of Gastroenterology.2018; 53(7): 849. CrossRef
Global elimination of hepatitis C virus infection: Progresses and the remaining challenges
Reza Taherkhani, Fatemeh Farshadpour
World Journal of Hepatology.2017; 9(33): 1239. CrossRef